All Immuno Content

Bringing you the latest research in immuno-oncology, autoimmunity, therapeutic modalities and more, through a range of Speaker Interviews, Industry Insights, and Expert Opinions.

Discussion Group Report
CAR T, the rockstar therapy of immuno-oncology, finds its next big challenge in translating research for use in solid tumours.
Edited by Tom Cohen |
23 June 2022
Translational & Preclinical Development
Commentary
Single-cell, real-time analysis of oncolytic viruses’ efficacy, and replication in living cancer cells.
14 June 2022
Translational & Preclinical Development
Discussion Group Report
Bringing together the experts to discuss the timeline of autoimmune disease therapeutics.
Edited by Tom Cohen |
25 May 2022
Autoimmunity & Immunology
Insight Article
What’s next for CAR T cell therapy? What’s the best way to develop combination therapies for multi-modal efficacy?
Edited by Tom Cohen |
20 May 2022
Tumour Microenvironment
Video Content
Video Q&A
Video Interview | Namir Hassan, CEO at Zelluna Immunotherapy
05 May 2022
Therapeutic Modalities
Discussion Group Report
Ian A Wilson of ImaginAb delivers the presentation ‘The Value of In Vivo Imaging on the Clinical Development of IO Drugs’ at Oxford Global’s discussion group.
Edited by Tom Cohen |
14 April 2022
Translational & Preclinical Development
Commentary
Oxford Global’s Immuno Week showcased new ways of reprogramming the immune system to treat malignancy with TCR-T.
Edited by Tom Cohen |
08 April 2022
Translational & Preclinical Development
Insight Article
Early and effective treatment of cancers could mean the difference between life and death. Therefore, companion diagnostics and biomarker discovery could be considered one of the most important avenues to explore in immuno-oncology.
Edited by Tom Cohen |
07 April 2022
Biomarkers in Immuno-Oncology
Insight Article
Experts discuss elusively successful therapies and the rising costs that come with new technologies.
Edited by Tom Cohen |
30 March 2022
Autoimmunity & Immunology
Commentary
RevoloBio’s autoimmunity drug, ‘1805, breaks with the mould in its revolutionary approach. With success in a Phase II clinical trial, scientists wonder what’s around the corner for the field.
Edited by Tom Cohen |
24 March 2022
Autoimmunity & Immunology

Search by Keyword

Filter by Subject Area

Filter by Content Type

We produce cutting edge congresses and summits for the Life Sciences Industry, bringing together industry leaders and solution providers at a senior level, creating the opportunity to partner, network and knowledge share.

Contact Us:

Copyright Oxford Global Marketing Limited. All rights reserved.

Member Community Login